This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Manage exacerbating copd patients

How should I manage exacerbating COPD patients?

Webinar | 19th Nov 01:00 PM GMT |

PM-IE-CPU-WCNT-190009

Register now

GSK respiratory products

GSK Respiratory

See the products in our Ellipta portfolio and find out how these can support you in treating your patients with Asthma and COPD.

Tivicay▼+ Lamivudine

For your HIV treatment-naïve adult patients, the next step in the 2-drug regimen era.

Learn more

Tivicay▼ (dolutegravir) Prescribing information

Epivir (lamivudine) Prescribing information

Explore Bexsero - Meningococcal Group B Vaccine

Bexsero is indicated for the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease(IMD) caused by Neisseria meningitidis group B.

Learn more

Prescribing information

Using dual therapy or triple therapy for your patients?

The IMPACT trial was the first trial to assess the efficacy and safety of single inhaler Triple Therapy TRELEGY▼ Ellipta vs. an ICS/LABA (FF/VI 92/22 mcg) and a LAMA/LABA (UMEC/VI).1

Explore the IMPACT data

Prescribing information

Chat Icon

Click-To-Chat


Connect with a member from the GSK Medical Information team using our LiveChat Service.

Click here

 

Abbreviations

FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol

References:

  1. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.